

FOR IMMEDIATE RELEASE

6th September 2019

Glycostem awarded €5 million for clinical activities

6th September 2019, Oss, The Netherlands — Glycostem Therapeutics BV, a clinical stage and leading NK-cell company, today announced they have been awarded a €5 million loan from RVO's Innovation Credit budget for clinical trials. This is the highest possible award a company can be given.

Troels Jordansen, CEO said “This is the second time we have applied and been awarded loan under the Innovation Credit scheme. The first was a smaller Technical programme helping to fund out closed system and GMP compliant manufacturing set-up. This programme was completed on time and budget. Our second successful application is to co-fund our pivotal clinical trials leading to product approval in '23.”

“Without funding options like Innovation Credit, small companies like Glycostem would find it difficult to fund the larger ticket budget items like pivotal trials. We are delighted to have secured this funding so we can initiate our trials and make safe, cost effective and promising immunotherapy products available for severely unmet clinical needs.” finished Troels Jordansen.

- end -



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com

About Glycostem

Netherlands-based Glycostem Therapeutics BV, a clinical stage biotech company, develops allogeneic cellular immunotherapy to treat several types of cancer. By harnessing the power of stem cell-derived Natural Killer (NK) cells, Glycostem's products are a safer alternative to CAR-T-cells as there are no Graft versus Host Disease. Glycostem's lead product, oNKord[®], is manufactured from allogeneic raw material and is available off-the shelf.

oNKord[®] is produced in a closed system in Glycostem's state-of-the-art and GMP (Good Manufacturing Process) licensed production facility in the Netherlands, from which it can be distributed globally. The production technology includes *ex vivo* generation of high numbers of NK-cells with a high degree of purity for clinical applications. oNKord[®] successfully passed phase I clinical trial (elderly and frail AML - Acute Myeloid Leukemia - patients), providing solid safety data and strong indication of clinical activity, including response on MRD (Minimal Residual Disease). Results indicate that oNKord[®] may be safely infused in patients with AML patients.

Glycostem is furthermore developing a range of CAR-NK products in-house and in cooperation with global partners including MolMed SPA (BIT:MLM).

Thanks to its nine patent families, longstanding technical expertise and resources, as well as 'Orphan Drug Designation', Glycostem has secured a leadership position in the global NK-cell market.



Contact:

Troels Jordansen +31 6 1834 5326 - Troels@Glycostem.com – www.Glycostem.com